Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis

Silvia Molteni, Eva RealiLaboratory of Translational Immunology, Istituto Ortopedico Galeazzi, Milan, ItalyAbstract: Development of psoriasis results from a complex interplay between genetically predisposing factors and environmental triggers that give rise to a self-sustaining pathogenic cycle invo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Molteni S, Reali E
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/ce060f341bd64b119b366aa141be5d99
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ce060f341bd64b119b366aa141be5d99
record_format dspace
spelling oai:doaj.org-article:ce060f341bd64b119b366aa141be5d992021-12-02T01:25:56ZBiomarkers in the pathogenesis, diagnosis, and treatment of psoriasis2230-326Xhttps://doaj.org/article/ce060f341bd64b119b366aa141be5d992012-09-01T00:00:00Zhttp://www.dovepress.com/biomarkers-in-the-pathogenesis-diagnosis-and-treatment-of-psoriasis-a10900https://doaj.org/toc/2230-326XSilvia Molteni, Eva RealiLaboratory of Translational Immunology, Istituto Ortopedico Galeazzi, Milan, ItalyAbstract: Development of psoriasis results from a complex interplay between genetically predisposing factors and environmental triggers that give rise to a self-sustaining pathogenic cycle involving T cells, dendritic cells, connective tissue, and skin epithelium. From 5% to 40% of patients with psoriasis also develop psoriatic arthritis, and increasing evidence indicates an association with other systemic manifestations, including cardiovascular disease and the metabolic syndrome. In psoriatic disease, there is a need for development of biomarkers for assessment of disease severity, for prediction of the outcome of therapeutic interventions, and for distinction between the different clinical variants of the disease. A field of great importance is identification of biomarkers for prediction of development of comorbidities, such as arthritis, cardiovascular disease, and the metabolic syndrome. Genetic determinants of psoriasis and their products not only give an important insight into the pathogenesis of the disease, but may also function as markers of risk for developing cutaneous psoriasis or psoriatic arthritis. So far, there are limited validation data to support the use of candidate biomarkers in clinical practice. Here we review the data from several studies on some of the most promising candidate biomarkers for cutaneous psoriasis and psoriatic arthritis, for the detection of systemic inflammation, and for use as endpoints for therapeutic interventions. Attention is focused on the molecules that take part in the interplay giving rise to psoriasis and on gene products that may represent a link between predisposing genetic factors and the immune and inflammatory processes involved in pathogenesis of the disease. Finally, we provide an overview on how biomarkers can offer insights into the pathogenesis and natural history of psoriasis.Keywords: psoriatic disease, genetic markers, tissue-associated biomarkers, serum biomarkers, predictive factors, comorbiditiesMolteni SReali EDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2012, Iss default, Pp 55-66 (2012)
institution DOAJ
collection DOAJ
language EN
topic Dermatology
RL1-803
spellingShingle Dermatology
RL1-803
Molteni S
Reali E
Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
description Silvia Molteni, Eva RealiLaboratory of Translational Immunology, Istituto Ortopedico Galeazzi, Milan, ItalyAbstract: Development of psoriasis results from a complex interplay between genetically predisposing factors and environmental triggers that give rise to a self-sustaining pathogenic cycle involving T cells, dendritic cells, connective tissue, and skin epithelium. From 5% to 40% of patients with psoriasis also develop psoriatic arthritis, and increasing evidence indicates an association with other systemic manifestations, including cardiovascular disease and the metabolic syndrome. In psoriatic disease, there is a need for development of biomarkers for assessment of disease severity, for prediction of the outcome of therapeutic interventions, and for distinction between the different clinical variants of the disease. A field of great importance is identification of biomarkers for prediction of development of comorbidities, such as arthritis, cardiovascular disease, and the metabolic syndrome. Genetic determinants of psoriasis and their products not only give an important insight into the pathogenesis of the disease, but may also function as markers of risk for developing cutaneous psoriasis or psoriatic arthritis. So far, there are limited validation data to support the use of candidate biomarkers in clinical practice. Here we review the data from several studies on some of the most promising candidate biomarkers for cutaneous psoriasis and psoriatic arthritis, for the detection of systemic inflammation, and for use as endpoints for therapeutic interventions. Attention is focused on the molecules that take part in the interplay giving rise to psoriasis and on gene products that may represent a link between predisposing genetic factors and the immune and inflammatory processes involved in pathogenesis of the disease. Finally, we provide an overview on how biomarkers can offer insights into the pathogenesis and natural history of psoriasis.Keywords: psoriatic disease, genetic markers, tissue-associated biomarkers, serum biomarkers, predictive factors, comorbidities
format article
author Molteni S
Reali E
author_facet Molteni S
Reali E
author_sort Molteni S
title Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
title_short Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
title_full Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
title_fullStr Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
title_full_unstemmed Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
title_sort biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/ce060f341bd64b119b366aa141be5d99
work_keys_str_mv AT moltenis biomarkersinthepathogenesisdiagnosisandtreatmentofpsoriasis
AT realie biomarkersinthepathogenesisdiagnosisandtreatmentofpsoriasis
_version_ 1718403103223447552